Exploring the Gut Microbiome and Its Role in Oncology – Interview with Dr. Michael Liss
Discover how the gut microbiome impacts cancer risk, treatment response, and prevention strategies. Dr. Michael Liss explains the role of microbiome testing, personalized interventions, and the innovative Oncobiomix platform in supporting patients on their cancer journey.
Introduction
The gut microbiome has emerged as a pivotal factor in oncology, influencing cancer risk, progression, and treatment outcomes. Dr. Michael Liss, founder of Oncobiomix, shares his insights on how microbiome analysis can complement traditional cancer care, guide personalized interventions, and help patients navigate their cancer journey more effectively.
1. The Microbiome’s Influence on Clinical Oncology
Interviewer: Dr. Liss, can you share your insights on the current understanding of the gut microbiome’s influence on clinical oncology? Why is this area becoming increasingly important in cancer research?
Dr. Michael Liss: Microbiome is the hot topic because it has the potential to completely change the field of oncology. We have known for years that lifestyle factors and genetics play important roles in the cancer journey. The microbiome lies at the intersection of these factors, and the excitement surrounds the ability to alter the microbiome to impact various aspects of cancer care.
2. Microbiome Impact on Cancer Risk and Treatment
Interviewer: How does the gut microbiome impact cancer risk, progression, and treatment response, particularly in immunotherapy and chemotherapy?
Dr. Michael Liss: We are seeing major strides in immunotherapy just by providing helpful bacteria. While fecal transplant has had some success in clinical trials, it’s unlikely to be a sustainable option. Understanding why it works is still a challenge. Bacteria interact with our gut-associated lymphoid tissue, which trains the immune system.
Dr. Michael Liss: On the chemotherapy side, the microbiome may influence toxicity. Poor gut bacteria at baseline can increase GI side effects like diarrhea, affecting the ability to complete standard-of-care treatments and overall outcomes.
3. Promising Developments in Microbiome Research
Interviewer: From your perspective, what are the most promising developments in microbiome research that could redefine cancer prevention and treatment?
Dr. Michael Liss: Microbiome testing allows us to pinpoint wellness factors now. Treatments targeting the microbiome are under investigation. While regulatory hurdles exist, rationally designed probiotics, or live bacterial therapeutics, are likely the next step.
4. Predictive Power of Microbiome Profiles
Interviewer: In what ways can microbiome profiles serve as predictive indicators for treatment efficacy or potential medication side effects?
Dr. Michael Liss: Research is identifying “good” and “bad” bacteria, helping predict who may experience higher toxicity. Toxicity matters because stopping treatment early reduces effectiveness. Lifestyle recommendations to increase beneficial bacteria and reduce harmful ones may lower toxicity risk. Like any ecosystem, changing one element can have ripple effects, making microbiome research both fascinating and complex.
Oncobiomix: Personalized Microbiome Insights
Interviewer: What motivated you to develop Oncobiomix, and how does this platform utilize microbiome data for personalized cancer care?
Dr. Michael Liss: My patients motivated me. They often asked, “What should I eat?” or “Any dietary recommendations?” Generic advice wasn’t enough—they wanted personalized guidance. Oncobiomix, combining “onco” and “biomix,” provides microbiome-based insights. It’s not a treatment for cancer, but it empowers patients and providers to make informed lifestyle choices during treatment.
5. Advantages of Microbiome Testing
Interviewer: Can you explain the specific advantages of using microbiome-based testing in tailoring options during the cancer journey?
Dr. Michael Liss: Microbiome testing gives a baseline, allows changes, and enables retesting—a “biome-marker,” similar to other biomarkers. It provides tangible data alongside symptom management, offering a novel tool for lifestyle support. Lack of symptoms doesn’t necessarily mean a healthy balance, which is why this testing is valuable.
6. PRIMUS and RebiomX Testing Kits
Interviewer: Could you describe the process of creating the PRIMUS and RebiomX gut microbiome testing kits? What are their key features and benefits?
Dr. Michael Liss: PRIMUS: Developed for prostate cancer risk assessment, currently undergoing clinical validation. Provides a score and recommendations to modify risk.
Dr. Michael Liss: RebiomX: Used with Blueprint to Beat Cancer, this functional test identifies bacteria and includes mineral and biosynthesis pathway analyses, enabling more tailored recommendations.
7. Relevance to Blueprint to Beat Cancer
Interviewer: Why is the gut microbiome fundamental to the work that Blueprint to Beat Cancer is doing in systemic, early, and personalized cancer prevention?
Dr. Michael Liss: Blueprint integrates wellness applications with clinicians’ treatment regimens and screening strategies. Microbiome insights complement these approaches, allowing personalized interventions alongside standard-of-care treatments. Our collaboration ensures the testing is user-friendly, actionable, and continually improving.
8. Complementing Genomic and AI Strategies
Interviewer: How can microbiome analysis complement the genomic and AI-driven strategies that Blueprint to Beat Cancer employs to identify and support at-risk populations?
Dr. Michael Liss: The microbiome sits at the intersection of genetics and lifestyle. Ignoring it leaves a major gap in wellness interventions. The more data we have—from genes to microbes—the more personalized and effective a patient’s plan can be.
9. Future Opportunities in Microbiome Research
Interviewer: Looking ahead, what do you see as the most significant opportunities for microbiome research to revolutionize clinical oncology?
Dr. Michael Liss: Understanding how microbes interact with the immune system will be profound. It’s a frontier that could change prevention, treatment, and supportive care in cancer.
